Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

736
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
736
Cancer Vaccines01:30

Cancer Vaccines

562
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
562
Vaccinations01:51

Vaccinations

46.2K
Overview
46.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A metabolically reprogrammable nanoplatform potentiates photodynamic immunotherapy through glycolytic blockade.

Biomaterials·2026
Same author

Lysosome self-sorting nanodegraders for hepatic clearance of pathogenic serum mediators.

Nature nanotechnology·2026
Same author

A Dimer for Dinner: The Impact of GHS-R1a Heterodimerization on Feeding Circuits.

Biomolecules·2026
Same author

Network-based analysis of crucial genes for salt tolerance in rice.

Plant physiology·2026
Same author

Phototheranostic Sutures Integrated with NIR-II Emissive Photosensitizers for Postoperative Complication Prevention and Non-invasive Monitoring.

Journal of the American Chemical Society·2026
Same author

Tumor-Specific Delivery of CD28 siRNA via Lyso-PC C-16 Modified Lipid Nanoparticles Overcomes Anti-PD-1 Resistance by Remodeling Tumor Microenvironment.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Related Experiment Video

Updated: Oct 15, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K

Aggregation-Induced Emission-Based Vaccine Improves Potential Antitumor Immunotherapy.

Yong Liang1, Huanle Gong2, Yan Li3

  • 1Central and Clinical Laboratory, The Affiliated Huaian Hospital of Xuzhou Medical University and Huaian Second Hospital, Huaian, 223002, China.

Journal of Biomedical Nanotechnology
|October 28, 2021
PubMed
Summary

This study introduces a novel biomaterial-based vaccine using near-infrared-emitting AIEgens (TPE-Ph-DCM) to boost anti-tumor immune responses. The developed photodynamic vaccine effectively inhibited tumor growth in mice, paving the way for advanced cancer immunotherapies.

More Related Videos

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.7K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.7K

Related Experiment Videos

Last Updated: Oct 15, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.6K
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
08:02

In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells

Published on: September 23, 2021

2.7K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.7K

Area of Science:

  • Biomaterials Science
  • Immunology
  • Cancer Research
  • Nanotechnology

Background:

  • Biomaterial-based immunomodulation shows promise for cancer prevention and treatment.
  • Current tumor vaccines are less developed than those for infectious diseases.
  • Developing effective adjuvants is crucial for enhancing anti-tumor immune responses.

Purpose of the Study:

  • To design and evaluate a novel near-infrared-emitting Aggregation-Induced Emission (AIE) gen-based vaccine (TPE-Ph-DCM) as an adjuvant.
  • To investigate the vaccine's ability to enhance antigen presentation and T-cell responses.
  • To assess the prophylactic and therapeutic efficacy of the AIE-based vaccine in a mouse tumor model.

Main Methods:

  • Synthesis of a near-infrared-emitting AIEgen (TPE-Ph-DCM) for vaccine development.
  • Evaluation of the vaccine's effect on dendritic cell (DC) antigen presentation.
  • Assessment of antigen-specific cytotoxic T lymphocyte (CTL) functionality.
  • In vivo studies using a B16-OVA mouse model for prophylactic and therapeutic evaluation.

Main Results:

  • The AIE-based photodynamic vaccine significantly enhanced DC antigen presentation.
  • It effectively elicited antigen-specific cytotoxic T lymphocyte (CTL) functionality.
  • The vaccine demonstrated significant inhibition of B16-OVA tumor growth both prophylactically and therapeutically in mice.

Conclusions:

  • The developed TPE-Ph-DCM AIEgen-based vaccine acts as a potent adjuvant, enhancing anti-tumor immunity.
  • This study provides a scientific foundation for creating effective and safe tumor vaccines.
  • AIEgens offer a promising platform for developing next-generation cancer immunotherapies.